SILLAJEN BIOTHERAPEUTICS, INC. Patent applications |
Patent application number | Title | Published |
20160129135 | ONCOLYTIC VACCINIA VIRUS CANCER THERAPY - Embodiments of the invention are directed methods that include a thymidine kinase deficient vaccinia virus. The methods include administering the vaccinia virus at increased viral concentrations. Further aspects of the invention include methods for inducing oncolysis or collapse of tumor vasculature in a subject having a tumor comprising administering to a subject at least 1×10 | 05-12-2016 |
20160038548 | Systemic Treatment of Metastatic and/or Systemically-Disseminated Cancers Using GM-CSF-Expressing Poxviruses - The present invention concerns methods and compositions for the treatment of cancer and cancer cells using intravascular administration of a vaccinia virus. In some embodiments, methods and compositions involve a replicative vaccinia virus that encodes GM-CSF. | 02-11-2016 |
20150202325 | ONCOLYTIC VACCINIA VIRUS CANCER THERAPY - Embodiments of the invention are directed methods that include a thymidine kinase deficient vaccinia virus. The methods include administering the vaccinia virus at increased viral concentrations. Further aspects of the invention include methods for inducing oncolysis or collapse of tumor vasculature in a subject having a tumor comprising administering to a subject at least 1×10 | 07-23-2015 |